Transplant ineligible patients who are diagnosed with multiple myeloma (MM) are a diverse group; some are fit while some are very frail, which means one treatment does not fit all. In particular, a patient’s ability to travel frequently to the clinic for treatment is variable.
On March 11, 2024, the Multiple Myeloma Hub hosted a virtual symposium, “Current and future perspectives for bispecific antibodies in multiple myeloma: Learn…
The Multiple Myeloma Hub and Lymphoma Hub were pleased to speak to Anna Sureda, Catalan Institute of Oncology, Barcelona, ES. We asked, What is the…
During the Multiple Myeloma Hub virtual symposium, Naresh Bumma, The Ohio State University, Columbus, US, delivered a presentation on BCMA-directed bispecific antibodies in MM.
Here, we summarize a publication by Mohty et al. in the British Journal of Haematology on patient-reported outcomes following treatment with elranatamab in the phase…
During the Multiple Myeloma Hub virtual symposium held on March 11, 2024, “Current and future perspectives for bispecific antibodies in multiple myeloma: Lea…
On March 11, 2024, the Multiple Myeloma Hub hosted a virtual symposium, “Current and future perspectives for bispecific antibodies in multiple myeloma: Learn…
Here, we summarize a subanalysis by Oriol et al. published in Clinical Lymphoma, Myeloma and Leukemia on the results of the OPTIMISMM trial by frailty…
The Multiple Myeloma Hub virtual symposium was chaired by Sagar Lonial, and featured expert presentations from Naresh Bumma, Amrita Krishnan, and Sergio Giralt.
Here, we summarize a multicenter, retrospective study conducted in France on the incidence and characteristics of infections following treatment with bispecific antibody therapy.
Here, we summarize a publication by Murugappan, et al. in Journal of Geriatric Oncology on a comparison between approaches to measuring frailty: the patient-reported frailty…
